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Abstract Autologous stem cell transplantation (ASCT) to
treat autoimmune diseases (AID) is thought to reset
immunological memory directed against autoantigens. This
hypothesis can only be studied indirectly because the exact
nature of the pathogenetic autoantigens is unknown in most
AID. Therefore, 19 children with juvenile idiopathic
arthritis (JIA) or systemic lupus erythematodes (SLE) and
10 adults with multiple sclerosis (MS) were vaccinated with
the T-cell-dependent neoantigen rabies and the recall
antigen tetanus toxoid after, respectively before, bone
marrow harvest. Both vaccinations were repeated after
ASCT. All except two of the responders mounted a primary
antibody response to rabies after revaccination, and 44% of
the responders mounted a primary antibody response to
tetanus boost after ASCT. These data show that immuno-
logical memory to a neoantigen is lost in most patients with
AID after immunoablative pretreatment; however, memory
to a recall antigen boosted before bone marrow harvest is
only lost in part of the patients. Disease progression was
arrested in all patients with JIA/SLE except one, but only in
a minority of MS patients. Clinical outcome on a per case
basis was not associated with the profile of the immune
response toward the vaccination antigens after ASCT.
Keyword Rabies.tetanus.vaccination.autologousstem
celltransplantation.autoimmunediseases.
antibodyresponse.invitroproliferation
Introduction
Autologous stem cell transplantation (ASCT) is studied
since 1996 as a therapeutical approach for several refractory
autoimmune diseases (AID). The efficacy of this treatment
has been demonstrated in phase II studies [1–5]. Nowadays,
more than 800 ASCTs have been performed worldwide for
the treatment of progressive AID [1]. Although the
pathogenesis of AID such as juvenile idiopathic arthritis
(JIA) and multiple sclerosis (MS) is not fully understood,
there is indirect evidence that a T cell dysregulation plays a
key role in the onset and probably also in the perpetuation
of the disease [6–8]. The therapeutical concept of ASCT is
based on the eradication of adaptive immunity, including
autoimmunity, by an immunoablative pretreatment of the
patient, followed by the reinstitution of an equilibrated
adaptive immunity without autoimmunity. Different treat-
ment protocols have been practiced [2, 9]. The majority of
recent studies consist of intensive immunosuppressive (also
called immuno- or lymphoablative) pretreatment, followed
by reinfusion of a T cell depleted autograft. These protocols
are based on results obtained in animal studies [10]. At least
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overall effect of ASCT for AID. First, the effect of in vivo
conditioning and ex vivo T cell depletion on the eradication
of immunological memory, and second, the reinstitution of
a well-regulated adaptive immunity with a repertoire not
causing AID. The first effect can only be evaluated
indirectly, i.e., by investigating the characteristics of the
immunological response to a test antigen, as proven
relevant autoantigens are not exactly known. The second
effect can only be studied by long-term follow-up of the
patient’s disease status. Therefore, 19 children with JIA or
systemic lupus erythematodes (SLE) and 10 adults with MS
were vaccinated with a T-cell-dependent neoantigen (ra-
bies) immediately after and with the recall antigen tetanus
toxoid (TT) before bone marrow harvest. After immuno-
ablative conditioning and T cell depleted ASCT patients
were revaccinated from 3 months after ASCT onwards with
TT, and at 6 months after ASCT with rabies. We tested the
hypothesis that an effective conditioning regimen and Tcell
depletion of the graft would result in the elimination of
antigen-specific memory T and B cells producing high-
avidity IgG antibodies. Consequently, the immune response
to rabies would show characteristics of a primary response
before and after ASCT. Finally, the course of the original
AID after ASCT was followed, and the therapeutical effect
of ASCT was correlated with the profile of the immune
response toward the vaccination antigens.
Materials and Methods
Study Population
Between March 1997 and July 2002, 19 children [17 JIA
and 2 SLE; 7 girls; median age 9 years (range 4–15)] and
10 adults with MS [7 women; median age 37 years (range
23–50)] from three different centers, were prospectively
enrolled into this study [4, 5]. Patient characteristics are
given in Table I. Median disease duration before transplan-
tation was 70 months (range 13–179) in JIA/SLE and
60 months (range 24–144) in MS patients. Immunomodu-
lating drugs were stopped 1 month before the bone marrow
harvest and the first rabies immunization. A written
informed consent was obtained from all patients and/or
their parents, and the Local Committee on Medical Ethics
approved the study. Furthermore, in 18 healthy volunteers
[9 women; median age 31 years (range 19–49)], both the B
and T cell immune responses to a single rabies vaccination
and a boost 3 months later were investigated. These results
served as reference data [11]. Before this study, neither the
patients nor the healthy controls had been exposed to rabies
or had been vaccinated with (inactivated) rabies vaccine.
Autologous Stem Cell Transplantation
ASCT was performed according to the European League
against Rheumatism (EULAR) and the European Group for
Blood and Marrow Transplantation (EBMT) guidelines for
bone marrow transplantation in AID [12–14]. In short, in JIA
and SLE patients, the conditioning regimen consisted of
antithymocyte globulin i.v. (rabbit-ATG, Imtix-SangStat,
Lyon, France) at days −9t o−6 (cumulative dose 20 mg/kg),
cyclophosphamide i.v. at days −5t o−2 (cumulative dose
200 mg/kg) and low dose total body irradiation at day −1
(4 Gy, single dose), followed by reinfusion of T cell depleted
autologous stem cells at day 0 [5, 15]. In MS patients, the
conditioning regimen consisted of horse antithymocyte glob-
ulin i.v. (ATG, Mérieux Marcy L’Etoile, France) at days −7t o
−3 (cumulative dose 75 mg/kg), cyclophosphamide i.v. at
days −4a n d−3 (cumulative dose 120 mg/kg) and high-dose
total body irradiation at days −2a n d−1i nt w of r a c t i o n so f
5 Gy daily, followed by reinfusion of the T cell depleted
a u t o g r a f ta td a y0[ 4]. Aspirates of unprimed bone marrow
were the source of autologous hematopoietic stem cells in all
patients. The bone marrow graft was depleted of mature T
cells by two different methods, i.e., either by T cell depletion
using immunorosette-sedimentation with specific monoclonals
(anti-CD2 and anti-CD3) coupled to autologous red blood
cells (n=16) or by positive CD34+ selection by CliniMACS
(Miltenyi Biotec, Munich, Germany; n=13), performed at
Sanquin Pharmaceutical Services (Sanquin, Amsterdam)
under Good Manufacturing Practice (GMP) conditions [16].
The T cell depleted graft was cryopreserved until further use.
Vaccines
The rabies vaccine used was the human diploid cell vaccine
(HDCV), manufactured by the Institute Pasteur Mérieux
MSD, Lyon, France (commercial lot number NO 976-8). It
is a safe and effective antigen for measurement of both B
and T cell immune responses to a neoantigen in healthy
individuals [11]. There are no contra-indications for
vaccination of immunocompromised patients [17, 18]. For
TT vaccination, DTP [National Institute for Public Health
and the Environment (RIVM), Bilthoven, The Netherlands]
was used, which contains diphtheria toxoid, TT, and
inactivated poliovirus types 1, 2, and 3. The DTP
vaccination before bone marrow harvest and ASCT was
considered to be a booster vaccination because all patients
have been vaccinated in the past as part of the national
vaccination program for children in The Netherlands.
Vaccination and Sampling Protocol
One milliliter of HDCV was given intramuscularly directly
after the bone marrowharvest (≥4 weeksbefore conditioning)
648 J Clin Immunol (2007) 27:647–658in the patients; this was repeated at 6 months after ASCT.
DTP vaccination was given at least 1 month before bone
marrow harvest and three subsequent DTP vaccinations
were given at 3, 4, and 5 months, respectively, after ASCT
(see Fig. 1). Blood samples were drawn at days 0 and 28
after each vaccination. Any adverse events were registered.
Sera were stored at −20°C and PBMC, obtained by Ficoll-
Isopaque gradient centrifugation, were viably stored in
liquid nitrogen. One MS patient turned out to have never
been vaccinated with TT in the past; her primary anti-TT
responses were not included in the analysis. Two MS
patients and five JIA patients were excluded from analysis
of antirabies immune responses because of incomplete
vaccination or sampling.
Antigen for in Vitro Assays
Rabies virus Pitman Moore (PM) strain (Wistar PM/WI-
38-1503-3 M) was propagated in primary dog kidney cells
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Fig. 1 Vaccination scheme. ASCT, autologous stem cell transplanta-
tion; TT0, tetanus vaccination pre ASCT (and before bone marrow
harvest); TT1, tetanus vaccination at 3 months post ASCT; TT2,
tetanus vaccination at 4 months post ASCT; TT3, tetanus vaccination
at 5 months post ASCT; R1, rabies vaccination after bone marrow
harvest; R2, rabies vaccination 6 months post ASCT. Conditioning:
ATG, anti-thymocyte globulins, CYC, cyclophosphamide, TBI, total
body irradiation.
Table I Patient Characteristics
Patient Diagnosis Sex Age at ASCT (years) Medication history before ASCT Dx–Tx (months)
1 MS F 48 MP 60
2 MS M 47 MP 60
3 MS F 44 MP, IFNβ 48
4 MS F 31 MP, IFNβ 60
5 MS F 37 MP 60
6 MS F 50 MP 48
7 MS F 41 MP, IFNβ, IVIG 24
8 MS M 23 MP, IFNβ, IVIG 72
9 MS F 34 MP, IFNβ 36
10 MS M 34 MP, IFNβ 144
11 sJIA F 7 NSAID, St, MTX, CsA, AZA, IVIG 69
12 pJIA F 8 NSAID, St, MTX, CsA, 47
13 sJIA M 11 NSAID, St, MTX, CsA, 108
14 sJIA F 11 NSAID, St, MTX, CsA, AZA, IVIG, SSZ 73
15 sJIA M 14 NSAID, St, MTX, AZA, SSZ, AURO 117
16 pJIA M 6 NSAID, St, MTX, SSZ 31
17 sJIA M 10 NSAID, St, MTX, CsA, AZA, CYC, HCQ, SSZ 71
18 sJIA M 9 NSAID, St, MTX, CsA, AZA, IVIG 55
19 sJIA F 15 NSAID, St, MTX, CsA, AZA, HCQ 135
20 pJIA M 12 NSAID, St, MTX, CsA, HCQ, SSZ, AURO 86
21 sJIA F 4 NSAID, St, MTX, CsA 36
22 sJIA F 5 NSAID, St, MTX, CsA 27
23 pJIA M 5 NSAID, St, MTX, CsA, SSZ 75
24 sJIA M 8 NSAID, St, MTX, CsA, anti-TNF-α 27
25 sJIA M 8 NSAID, St, MTX, CsA 80
26 sJIA M 4 NSAID, St, MTX, CsA 13
27 sJIA M 12 NSAID, St, MTX, CsA, anti-TNF-α 106
28 SLE M 15 NSAID, St, AZA, CYC, HCQ 175
29 SLE F 15 NSAID, St, AZA, IVIG, CYC 179
Anti-TNF-α anti-tumor necrosis factor alpha therapy, AURO auromyosine, AZA azathioprine, CsA cyclosporine A, CYC cyclophosphamide, Dx–
Tx months from diagnosis to ASCT, F female, HCQ hydroxychloroquine, INF β interferon β, IVIG intravenous immunoglobulins, M male, MP
methylprednisolone, MS multiple sclerosis, MTX methotrexate, NSAID non steroidal anti-inflammatory drugs, pJIA\ polyarticular JIA, sJIA
systemic JIA, St steroids, SLE systemic lupus erythematodes, SSZ sulfasalazine
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inactivated with β-propiolactone [19]. DKCV was used as
coating antigen in ELISA, and compared with the fifth
International Standard for Rabies Vaccine (Statens Serum
Institut, Copenhagen, Denmark, supplied by NIBSC,
Potters Bar, UK) [11, 20, 21]. The results obtained from
ELISA assays using either the fifth International Standard
for Rabies Vaccine or DKCV as coating material were
comparable (data not shown). The TT antigen stock
contained 150 Lf/ml (RIVM, [22]).
Antibody Quantification
Rabies
The concentrations of IgG, IgG subclasses, IgA, and IgM
antirabies antibodies were measured by sandwich ELISA
technique as described in detail previously [11]. The second
International Standard reference serum of the WHO
containing 30 IU/ml of total IgG antirabies [23] (Statens
Serum Institut) and an in house prepared secondary
reference serum (total IgG antirabies, 3.3 IU/ml) were used
to express the IgG data in IU/ml. For IgG subclass
antirabies and IgM and IgA antirabies, no reference sera
are available; therefore, our secondary reference serum was
used as standard, as described previously [11]. Indirectly,
IgG subclass antirabies could be expressed in IU/ml by
determination of the relative contribution of the IgG
subclasses to the total IgG antirabies response [11]. The
responder criteria for rabies are defined as a twofold
increase in antirabies antibody titer, either in IgM or IgG,
postvaccination. Criteria for a secondary response are the
concentration of antirabies antibodies and occurrence of an
isotype switch and avidity maturation [11].
Tetanus Toxoid
Quantification of IgG and IgG subclasses antibodies against
TT was performed with an antibody-capture enzyme-linked
immunosorbent assay, as previously described [22, 24]. In
short, 96-well polystyrene microtiter plates (Costar, Cam-
bridge, MA, USA) were coated with TT in a concentration of
1.5 Lf/ml in carbonate buffer pH 9.6 at 37°C for 3 h. After a
1-h blocking step with 1% bovine serum albumin (BSA,
Sigma, St Louis, MO, USA) in PBS, serum samples and
standard sera diluted in PBS/0.05% Tween 20 /1% BSAwere
added and incubated at 37°C for 2 h. The quantification of
IgG and IgG subclass anti-TT antibodies was according to
the method used for antirabies antibodies [11]. Reference
sera for TT were in house prepared secondary standards
calibrated on international standards [total IgG anti-TT
24 IU/ml (=122 μg/ml)]. The criteria for a tetanus response
after booster vaccination are defined as ≥1.25-fold increase in
anti-TT antibodies and a minimum titer of 5 μg/ml anti-TT
antibodies or a twofold increase in the antibody concentration
and a minimum titer of 1 μg/ml anti-TT antibodies [22]. A
primary response to tetanus after ASCT is defined as an
increase in antibody concentration as mentioned above in
combination with at least a 10% decrease in avidity index,
compared to the response upon TT vaccination before ASCT.
Antibody Avidity
In relevant cases, the avidity of IgG1 antirabies and IgG1
anti-TT was measured by a modified elution ELISA as
described in detail previously [11, 25]. In this assay,
antigen-bound antibodies were eluted with a range of
concentrations (range 0.5–4.5 M) of the chaotropic agent
sodium thiocyanate (NaSCN). The relative avidity index is
defined as the molarity of NaSCN at which 50% of the
amount of IgG subclass antibodies remains bound to the
coated rabies or tetanus antigen.
Lymphocyte Proliferation
Triplicate cultures of 1×10
5 PBMC per well were
performed in 96-well round-bottom microtiter plates (Co-
star) in a final volume of 200 μl RPMI 1640 glutamax 1
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
heat-inactivated pooled human AB serum, penicillin
(100 U/ml; Invitrogen) and streptomycin (100 μg/ml;
Invitrogen). Cells were stimulated with DKCV (0.5 μg/
ml) or TT (5 Lf/ml) for 5 days at 37°C and 5% CO2.
Subsequently, 1 μCi/well
3H-thymidine (Amersham, San
Francisco, CA, USA) was added 18 h before harvesting.
3H-thymidine uptake of cultured PBMC was measured as
counts per minute (cpm) of triplicate cultures by liquid
scintillation counter (Wallac, Turku, Finland) and expressed
as a stimulation index (SI; ratio mean cpm antigen/mean
cpm medium). SI≥3.0 was considered as evidence of
antigen-induced proliferation. As positive control, the pro-
liferative capacity of the PBMC was tested after mitogenic
or polyclonal stimulation, using phytohemagglutinin (PHA,
5 μg/ml Murex, Dartford, England) or anti-CD3 monoclo-
nal antibody (coat 0.1 μg/ml OKT3), followed by
3H-
thymidine incorporation at day 4 [11].
Statistical Analysis
The geometrical mean titer (GMT), with its 95% confidence
interval (CI), expressed in IU/ml for IgG and IgG subclasses
and in U/ml for IgA and IgM antirabies, and in μg/ml for
IgG and IgG subclasses anti-TT antibodies, were calculated
for each time-point of sampling. Differences between time-
points with respect to GMT values for all parameters were
assessed by the paired Student’s t test. The differences
650 J Clin Immunol (2007) 27:647–658between a primary and secondary immune response, i.e.,
concentration of antibody levels, isotype switch and avidity
maturation, were evaluated using the paired t test. Differ-
ences between groups were determined with an independent
t test. Lymphocyte proliferative responses after first and
booster vaccination were compared by the paired t test.
Statistical analysis was carried out using SPSS 12.0.1; p<
0.05 was considered to be statistically significant.
Results
Transplant Procedure and Outcome
Data on the immunological responses (B and T cellular)
after vaccination and on the clinical outcome of the patients
at 2 years post-ASCT are given in Table II. More details on
the clinical course of the patients with JIA and MS were
published previously [4, 5]. The graft contained a median
number of 1.5×10
6 CD34+ cells/kg body weight (range 0.4
to 6.0×10
6) in JIA/SLE patients and a median number of
1.1×10
6 CD34+ cells/kg body weight (range 0.4 to 1.9×
10
6) in MS patients. T cell depletion was achieved, leaving
a median of 2.2×10
4 CD3+ cells/kg body weight (range 0.2
to 35.4×10
4) in the graft of JIA/SLE patients and about
0.4×10
4 CD3+ cells/kg body weight (range between the
detection level of 0.3 and 3.3×10
4) in MS patients. The
immunoablative conditioning resulted in loss of virus-
specific immunological memory, as evidenced by a high
frequency of reactivation of herpetic viruses, as published
previously [4, 5]. Early after transplant two JIA patients
died due to a fatal macrophage activation syndrome (MAS)
Table II Immune Response to TT and Rabies and Clinical Outcome After ASCT
Patient Diagnosis Humoral responders post-ASCT Clinical outcome 2 years post
ASCT
Follow-up
(months)
TT Primary reponse
TT
Rabies Primary response
rabies
1M S + − nv nv Progressive 97
2M S + + − ne Stable 94
3 MS pv ne + + Progressive 86
4M S − ne + + Improved 81
5M S − ne + + Improved 79
6M S − ne + + Progressive 76
7M S − ne + + Progressive 61
8 MS + + nv nv Progressive 59
9M S − ne − ne Progressive 55
10 MS − ne − ne Progressive 54
11 sJIA + + nv nv Remission 118
12 pJIA + − nv nv Remission 116
13 sJIA + − nv nv Partial responder 111
14 sJIA + − + + Remission 107
15 sJIA + − + + Remission 106
16 pJIA + − + − Partial responder 104
17 sJIA + − + + Partial responder 103
18 sJIA + + + + Remission 99
19 sJIA Deceased Deceased Deceased Deceased Deceased (MAS) 4
20 pJIA + − + + Remission 95
21 sJIA + + + + Remission 87
22 sJIA + + + −
a Partial responder 79
23 pJIA + − + + Partial responder 79
24 sJIA + − + + Remission 77
25 sJIA + + nv nv Failure/ongoing disease 72
26 sJIA Deceased Deceased Deceased Deceased Deceased (MAS) 0.6
27 sJIA + + + + Remission 67
28 SLE + ne + + Partial responder 92
29 SLE + ne + + Remission 98
Partial responder: partial response was defined as improvement of disease activity according to the core set variables after reinstitution on low
dose DMARDS or steroids after a relapse [5]. Clinical outcome at 24 months after ASCT is indicated
MAS macrophage activation syndrome, MS multiple sclerosis, ne not evaluable because of no response or too low antigen-specific antibody titers
for measurement of avidity, nv not vaccinated, pJIA polyarticular JIA, pv primary vaccination, sJIA systemic JIA, TT tetanus toxoid
aParticular patient with a second BM harvest after rabies vaccination (see Fig. 6)
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and rabies data pre-ASCT are included for analysis. No
adverse effects were reported in patients after rabies and
DTP vaccinations. Reconstitution of different lymphoid
subsets, including CD3+ T cells and CD19+ B lympho-
cytes, was determined in absolute cell counts per microliter
blood by flow cytometry. At time of TT revaccination,
3 months post-ASCT, median CD3+ T cells counts were
Fig. 2 Total IgG response to tetanus and rabies in JIA/SLE and MS
patients. Individual data and geometric mean titer (GMT responders,
solid lines; GMT whole cohort, dashed lines) of IgG anti-TT (ig/ml)
and IgG and IgM antirabies (IU/ml and U/ml, respectively) for
children (JIA/SLE) and adult (MS) patients are depicted. Gray-shaded
area in upper part of figure represents the total IgG anti-TT response
in healthy adults to a TT booster vaccination with its 95% confidence
interval (CI). TT0, tetanus vaccination pre ASCT (and before bone
marrow harvest); TT1, tetanus vaccination at 3 months post ASCT;
TT2, tetanus vaccination at 4 months post ASCT; TT3, tetanus
vaccination at 5 months post ASCT. Gray-shaded area in middle
and lower part of figure represents the 95% CI for the primary and
secondary IgG and IgM response to rabies and the 95% CI in healthy
adults, respectively. R1, rabies vaccination after bone marrow harvest;
R2, rabies vaccination 6 months post ASCT. Horizontal dashed line
represents WHO seroconversion level (IgG antirabies 0.5 IU/ml) [11],
open diamonds represent non-responders, filled diamonds represent
responders.
652 J Clin Immunol (2007) 27:647–658215/μl (range 22 to 3,363) for JIA/SLE patients and 354/μl
(range 100 to 1,040) for MS patients. Three months post-
ASCT median CD19+ B cell counts were 129/μl (range 2
to 690) for JIA/SLE patients and 143/μl (range 59 to 424)
for MS patients. At the time of revaccinations post-ASCT
all patients showed normal in vitro proliferative responses
of PBMC after mitogenic or polyclonal stimulation (data
not shown).
Humoral Response to Vaccinations
Tetanus Toxoid
In Fig. 2 (upper part), the humoral response (total IgG) to TT
upon vaccination before bone marrow harvest and after
ASCT for children with JIA/SLE and adults with MS is
shown. All but one JIA and all MS patients responded to the
TT vaccination pre-ASCT (p=0.01 and p=0.04, respective-
ly). The antibody concentrations after vaccination of most
patients are within the range of TT booster responses in
healthy adult controls (gray shaded area upper part of
Fig. 2)[ 22]. After the conditioning regimen, the concentra-
tion of total IgG anti-TT in JIA/SLE patients decreased to
the same level as before vaccination before the bone marrow
harvest (p=0.74). A significant and increasing response to
TT was found after subsequent vaccinations 3, 4, and
5 months post-ASCT (TT3 versus TT1 p=0.01). In the
pediatric cohort, all 17 evaluable patients could be classified
as responders after one to three booster vaccinations post-
ASCT (Table II and Fig. 3). In two SLE responders, the
avidity index could not be measured due to low antigen-
specific antibody titers. Based on the avidity index, 6 of the
remaining 15 JIA/SLE responders showed characteristics of
a primary antibody response (40%), 9 showed character-
istics of a secondary response (60%, data not shown).
In MS patients, the concentration of total IgG anti-TT
antibodies after conditioning and before revaccination post-
ASCT decreased to 39% (p=0.02) of the amount measured
post-TT vaccination before ASCT. This is comparable to
what has been reported in healthy adults 12 months after
TT booster vaccination [22]. In contrast to the JIA/SLE
cohort, only three out of nine evaluable MS patients (33%)
could be classified as responders after two to three booster
vaccinations (Table II and Fig. 3). Two of them showed
characteristics of a primary antibody response based on a
decrease in avidity index.
Rabies
IgG and IgM antirabies antibody responses of JIA/SLE and
MS patients are shown in Fig. 2 (middle part and lower
part,respectively). As inhealthycontrols[11], IgG antirabies
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Fig. 3 Cumulative response
rate to tetanus and rabies in
JIA/SLE and MS post-ASCT.
The cumulative percentage of
responders is indicated for both
patient cohorts (dark gray rep-
resent children, light gray rep-
resent adults). TT0, tetanus
vaccination pre ASCT (and be-
fore bone marrow harvest); TT1,
tetanus vaccination at 3 months
post ASCT; TT2, tetanus vacci-
nation at 4 months post ASCT;
TT3, tetanus vaccination at
5 months post ASCT. R1, rabies
vaccination after bone marrow
harvest; R2, rabies vaccination
6 months post ASCT.
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found in IgG3, and no antibodies were detectable in IgG2
and IgG4 (data not shown). After the first rabies vaccination
before ASCT 86% (12/14) of JIA/SLE patients and 100%
(8/8) of MS patients could be classified as responder (p=
0.03 and p=0.04, respectively; Figs. 2 and 3), compared
with 100% of healthy controls [11]. After conditioning, the
antibody titers decreased to prevaccination levels in all
patients. After a second rabies vaccination at 6 months post-
ASCT, all evaluable JIA/SLE patients fulfilled the criteria
for responder, compared to five of eight MS patients (63%;
Fig. 2, middle part, and Fig. 3). In only 1 of the 12
responders of the JIA/SLE cohort and in none of the re-
sponders of the MS cohort, a significant increase in avidity
index of IgG1 antirabies after secondary vaccination post-
ASCT was observed (Fig. 4). The median avidity index of
IgG1 antirabies pre- and post-ASCT for the JIA/SLE cohort
was 0.7, median avidity index was 0.6 pre-ASCT and 0.7
post-ASCT for the MS group, comparable to the avidity
index in healthy adults after a first vaccination [11]. In most
JIA/SLE patients and MS patients an IgM response to rabies
was present pre- and post-ASCT (Fig. 2, lower part). An
isotype switch from IgM to IgG was not observed after
ASCT.
T cell Response to Vaccinations
PBMC from six JIA and all MS patients were available and
could be tested for in vitro proliferative T cell responses to
rabies and TT. Results are shown in Fig. 5. Before TT
vaccination pre-ASCT, a proliferative response to tetanus
(SI>3) could be elicited in all JIA patients [SI JIA cohort
geometric mean (GM) 33.2, range 19.7 to 59.4] and MS
patients (SI MS cohort GM 14.1, range 5.7 to 107.7). After
conditioning a significant decrease in SI was found at
3 months post-ASCT in both patient groups (SI JIA cohort
GM 1.7, range 0.8 to 3.9, SI MS cohort GM 2.6, range 1.0
to 8.6; total patient cohort p=0.01). Before revaccination
post-ASCT in two of four JIA patients and in seven of ten
MS patients, no antigen-specific proliferative response
could be detected. After one TT revaccination, a prolifer-
ative response was found in all patients, except one MS
patient (Fig. 5; p=0.02).
At 4 weeks after primary rabies vaccination before
ASCT, two of five JIA patients (SI JIA cohort GM 1.8,
range 0.5 to 7.8) and three of seven MS patients (SI MS
cohort GM 2.0, range 0.4 to 35) showed a SI≥3. Four
weeks after a rabies revaccination post-ASCT, one of five
JIA patients (SI JIA cohort: GM 1.5, range 0.9 to 4.4) and
one of nine MS patients (SI MS cohort: GM 2.1, range 0.8
to 20.6) showed a proliferative response (Fig. 5). No
significant increase in the proliferative response after rabies
revaccination was observed (p=0.57).
Course of the Disease and Responses to TT and Rabies
Vaccination
No clear relation could be found between clinical outcome at
24 months after ASCT and characteristics of the immune
response to vaccinations in the JIA/SLE and MS cohorts (see
Table II). In the JIA/SLE cohort, six patients showed a
primary anti-TT humoral response after ASCT; four of them
were in remission, one was a partial responder, and one had
ongoing disease activity. Nine JIA/SLE patients showed a
memory anti-TT response; five of them were in remission,
four were classified as partial responders. After ASCT, 11
JIA/SLE patients showed a primary humoral antirabies
response; 8 of them were in remission, and 3 were partial
responders. One JIA patient showed an increase in avidity
index after rabies booster post-ASCT; this patient was
classified as a partial responder. In another particular JIA
patient (patient 22, Tables I and II) a memory response upon
rabies vaccination after ASCT, characterized by a fast rise of
antibody titer at 1 week combined with a clear increase in
avidity of antirabies antibodies, could be observed (Fig. 6).
In this case, bone marrow had to be harvested twice because
of an intermediate change of the strategy of T cell depletion
of the graft, as described in an amended protocol after the
occurrence of lethal MAS in two cases [5, 26]. However, in
this particular patient, the first rabies vaccination had already
been given after the first harvest. The second graft,
theoretically containing rabies-specific memory B and T
cells, was used for transplantation. Three of nine MS patients
were TT responders post-ASCT (Table II); two of them
showed a primary anti-TT humoral response (one with
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Fig. 4 Relative avidity index of IgG1 antirabies in JIA/SLE and MS
patients. Relative avidity index (M NaSCN) of IgG1 antirabies in JIA/
SLE (children) and MS (adults) patients after a primary and booster
rabies vaccination pre- and post-ASCT, respectively. Gray-shaded
area represents the 95% CI for the avidity index for IgG1 antirabies
measured after a primary and booster vaccination with rabies in
healthy adult controls [11].
654 J Clin Immunol (2007) 27:647–658progressive disease and one with stable disease). The other
MS patient showing a memory anti-TT response post-ASCT
had progressive disease. All five rabies responders post-
ASCT in the MS cohort showed a primary response; three
with progressive disease and two with an improved course.
Despite a profound lymphopenia of CD4+CD45RA+ T cells
for at least 6–12 months in the whole group of patients [5,
27], no correlation was observed between the number of
CD4+ (CD4+CD45RO+ and CD4+CD45RA+) Tcells at the
time points of vaccination post-ASCT and the level of
antibody responses elicited to tetanus and rabies vaccination
(data not shown). In addition, no relation could be detected
between the number of CD3+ cells infused with the graft
and the clinical outcome.
Discussion
This study was performed to investigate the effect of
conditioning in vivo and graft manipulation ex vivo on the
elimination of adaptive immunological memory in the
setting of ASCT [15]. This was tested using two T-cell-
dependent vaccine antigens, the neoantigen rabies (HDCV)
[11] and the recall antigen TT, and specific antibody
production and antigen-stimulated T cell proliferation as
read-outs. Before ASCT, nearly all evaluable children (JIA/
SLE cohort) and all adult patients (MS cohort) mounted a
primary humoral response to rabies and a memory response
to TT and all patients mounted a cellular response to TT.
After ASCT, striking differences between the pediatric and
Fig. 5 Stimulation index (SI) of rabies and tetanus induced
proliferation in cultures of PBMC from JIA patients, MS patients.
Arrows indicate time-points of vaccinations. Gray-shaded area in
lower panel represents the SI after a single and booster rabies
vaccination in healthy adults with its 95% confidence interval (CI)
(11). Open diamonds represent nonresponders, closed diamonds
represent responders (SI≥3).
J Clin Immunol (2007) 27:647–658 655 655adult patient groups were observed: 100% of JIA/SLE
patients, but only 33% of the MS patients reached the
humoral responder status after the third tetanus revaccina-
tion (see Fig. 3). Based on avidity testing, about 56% of the
responders showed a memory response. All JIA/SLE
patients and 63% of the MS patients were able to respond
to the rabies vaccination at 6 months after ASCT. In all but
two the response to the rabies revaccination had character-
istics of a primary response, i.e., neither an isotype switch
from IgM to IgG nor avidity maturation had occured. These
data clearly show that in most cases, the immunological
memory to a T-cell-dependent neoantigen was eradicated
after conditioning. A vaccination with the T-cell-dependent
recall antigen TT was given shortly before bone marrow
harvest. Therefore, the response to TT after ASCT not only
reflects the effect of the conditioning, but also the potential
transfer of adaptive immunity by the graft. The humoral
response to TT was severely suppressed for a prolonged
period of time in MS patients; it was present in 60% in JIA/
SLE patients after the first revaccination and restored
rapidly after repeated vaccinations (see Fig. 3). The
deficient anti-TT antibody production in adult patients
may in part be explained by a higher IgG anti-TT titer
remaining present after ASCT and before revaccination,
compatible with an ongoing production of specific IgG
antibodies by radioresistent plasma cells [28–30]. This
phenomenon has also been observed in healthy multi-
vaccinated adults [22] and after ASCT for malignant
diseases in adults [31, 32]. Consistent with this is the
finding that preexisting oligoclonal IgG-bands remain
present for a long time in the cerebrospinal fluid in four
out of five of the included MS patients after ASCT [4]. This
was also observed by others [33, 34]. The meaning of the
latter finding for the course of the pathological process is
unclear. Two other factors possibly relevant for the obvious
difference in responses to a recall antigen in adults versus
children are the more intense conditioning and the more
rigorous T cell depletion of the graft in the MS cohort. The
biological effective dose (BED) of the TBI can be
calculated [35] to be 15 Gy in adults versus 5.6 Gy in
children. The former equals the intensity of myeloablative
pretreatment protocols for SCT in hematological malignan-
cies. The T cell depletion of the autograft in MS patients
was at least five times more rigorous than in children, and
probably prohibited any transfer of T cell memory. In fact,
similar findings were previously reported by our group and
others [36–41], after myeloablative conditioning, in vivo T
cell depletion and allogeneic or autologous SCT. The
transfer of a T-cell-dependent humoral memory response
after immunoablative conditioning and SCT with a not
rigorously T cell depleted graft (leaving 1.0×10
4 CD3+
cells/kg body weight) was demonstrated by chance in the
present study by the particular JIA case who was vaccinated
with rabies before the (second) bone marrow harvest: this
child mounted a secondary response after rabies revaccina-
tion post-ASCT (see Fig. 6). In conclusion, the results of
the present study indicate that immunoablative conditioning
may be sufficient to eliminate immunological memory
generated against a neoantigen given after graft harvest and
before conditioning. On the other hand, as illustrated by the
secondary humoral response to TT in 60% of the children
after ASCT, the same transplant procedure including
moderately stringent T cell depletion of the graft was
insufficient to eliminate immunological memory for a recall
antigen boosted before graft harvest. The therapeutical
effect on the disease was quite different between children
and adults: 16 out of 17 evaluable children were cured or
remitted of disease progression, whereas only 3 out of 10
evaluable adults improved or had stable disease during
follow-up. Whether the difference in kinetics of T-cell-
mediated immunological recovery after a transient suppres-
sion, i.e., more rapid in children than in adults, influenced
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Fig. 6 Antirabies and antitetanus response in a particular JIA patient.
One JIA patient was grafted with a second bone marrow harvest at
5 months before transplantation and after rabies as well as tetanus
vaccination. Arrows represent the time points of vaccination. The
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656 J Clin Immunol (2007) 27:647–658the post-ASCT course of the autoimmune disease cannot be
substantiated in this evaluative study. Apart from the
obvious differences in etiopathology of JIA/SLE and MS
other transplant-related factors may have contributed to the
disappointing therapeutical effect in MS patients. For
instance, the graft of children contained a higher number
of T cells than the graft of adults, due to differences in
depletion techniques. Although it is generally thought that
the recurrence of disease post-ASCT either reflects the
presence of autoagressive cells in the stem cell graft or the
persistence of these cells in the host, evidence is increasing
that further depletion of Tcells is not the way to improve the
outcome of ASCT and can possibly even lead to more
relapses, as seen in our MS patients; the lack of therapeutical
effect may be the result of the depletion of regulatory Tcells
[3, 42, 43]. Autoantigen-specific regulatory T cells have so
far not been studied in AID; the reappearance of nonspe-
cific CD25+FoxP3+ T cells after ASCT has been described
by de Kleer et al. [44], but their exact role in controlling
JIA is yet unknown. In MS, such studies have not been
performed. The severe and prolonged B and T cell immune
dysfunction following the intensive (rather myeloablative)
pretreatment of MS patients in this study, as shown by their
slow immune recovery for vaccine antigens following
ASCT, may have been inappropriate for a regulated and
equilibrated nonautoimmune restoration of their adaptive
immunity. Further study on autoantigen-specific regulatory
Tcells before and after ASCT in T-cell-dependent AID may
throw more light onto the mechanism behind dysregulated
immunity in these patients.
Concluding Remarks
Strong reduction in mature lymphocytes, including memory
cells, is likely to reduce the number of autoagressive
lymphocytes in patients with an immune-mediated disorder.
In the setting of ASCT, immunoablative conditioning
eliminated immunological memory for a neoantigen given
after the graft harvest, but did not consistently eliminate
immunological memory for a recall antigen, boosted before
harvest following nonrigorous T cell depletion of the
autograft. The clinical benefit of ASCT goes beyond mere
temporary suppression of adaptive immunity. It is hypoth-
esized that a relatively rapid recovery of the T cell immune
capacity, directed by a still adequately functioning thymus,
will lead to a diverse T cell repertoire, capable of differ-
entiating between foreign and own antigens, i.e., including
newly presented (formerly sequestered) autoantigens. On
the other hand, a delayed repopulation of the heavily de-
pleted host tissues by naïve selected T cells, including
regulatory T cells, may have missed the window of oppor-
tunity to regain tolerance to autoantigens.
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